---
title: A plain language summary of the TROPiCS-02 study in patients with breast cancer
  (HR-positive/HER2-negative)
date: '2024-01-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38270051/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240125170715&v=2.18.0
source: heidelberg[Affiliation]
description: 'WHAT IS THIS SUMMARY ABOUT?: Sacituzumab govitecan (brand name: TRODELVY^(®))
  is a new treatment for certain types of advanced or metastatic breast cancer. One
  common type of breast cancer has at least 1 of 2 hormone receptors (HR positive)
  and does not have human epidermal growth factor 2 (HER2 negative). The HR and HER2
  receptors are known to influence how severe a case of breast cancer is. Certain
  treatments will only work if a specific receptor is present on breast cancer ...'
disable_comments: true
---
WHAT IS THIS SUMMARY ABOUT?: Sacituzumab govitecan (brand name: TRODELVY^(®)) is a new treatment for certain types of advanced or metastatic breast cancer. One common type of breast cancer has at least 1 of 2 hormone receptors (HR positive) and does not have human epidermal growth factor 2 (HER2 negative). The HR and HER2 receptors are known to influence how severe a case of breast cancer is. Certain treatments will only work if a specific receptor is present on breast cancer ...